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Background: Diabetic patients with depression are often inadequately treated within primary care. These comorbid
conditions are associated with poor outcomes. The aim of this systematic review was to examine whether
collaborative care can improve depression and diabetes outcomes in patients with both depression and diabetes.
Methods: Medline, Embase, Cochrane library and PsyINFO were systematically searched to identify relevant
publications. All randomized controlled trials of collaborative care for diabetic patients with depression of all ages
who were reported by depression treatment response, depression remission, hemoglobin A1c (HbA1c) values,
adherence to antidepressant medication and/or oral hypoglycemic agent were included. Two authors
independently screened search results and extracted data from eligible studies. Dichotomous and continuous
measures of outcomes were combined using risk ratios (RRs) and mean differences (MDs) with 95% confidence
intervals (CIs) either by fixed or random-effects models.
Results: Eight studies containing 2,238 patients met the inclusion criteria. Collaborative care showed a significant
improvement in depression treatment response (RR = 1.33, 95% CI = 1.05-1.68), depression remission (adjusted
RR = 1.53, 95% CI =1.11-2.12), higher rates of adherence to antidepressant medication (RR = 1.79, 95% CI = 1.19-2.69)
and oral hypoglycemic agent (RR = 2.18, 95% CI = 1.61-2.96), but indicated a non-significant reduction in HbA1c
values (MD = -0.13, 95% CI = -0.46-0.19).
Conclusions: Improving depression care in diabetic patients is very necessary and important. Comparing with usual
care, collaborative care was associated with significantly better depressive outcomes and adherence in patients
with depression and diabetes. These findings emphasize the implications for collaborative care of diabetic patients
with depression in the future.
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Depression and diabetes mellitus (DM) are two of the
most prevalent chronic diseases around the world, which
frequently co-occur [1-5]. Approximately 20% of patients
with DM meet diagnostic criteria for depression [4,5].
Diabetic patients with depression are associated with
decreased glycated hemoglobin control, lower adherence
to diet, exercise and taking medications, comparing with
those without depression [6-9]. Moreover, depression had* Correspondence: guoaiminlaoshi@126.com
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reproduction in any medium, provided the oran increased risk in diabetes development and adverse dia-
betes outcomes, such like microvascular and macrovascular
complications [10,11].
Patients with diabetes and depression are usually poorly
managed in primary care [7,12]. Depression is associated
with failures to detect and diagnose in diabetic patients
[13]. Diabetes also weaken the effectiveness of depression
treatments [14,15]. Depression care needs to be improved
especially in people with diabetes and vice versa. The most
common method of treatments for diabetes and depression
in primary care are taking medications of oral hypoglycemic
agents and antidepressants. However, diabetes patients with
depression are more likely to have problems and concernsLtd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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than those patients without depression [1,15-17]. Conven-
tional psychological interventions fail to improve both
physical and mental health outcomes in diabetes patients
with depression [18].
Collaborative care is a new model pointing out coordi-
nated care management in primary practices, which
involving primary care physicians, nurses and other
specialists or professionals who provided patient-orientated
and guideline-based management to patients at the primary
care level [12,19-22]. It is originally conducted on depres-
sive patients. More studies of collaborative care have been
diversified to those patients with chronic illnesses [19,23].
Nowadays, collaborative care attracts a worldwide interest
in its potential effectiveness in achieving certain clinically
improvements and public health benefits [12,19-21,24,25].
Several randomized controlled trials (RCTs) indicated that
collaborative care significantly improved control of both
depression and diabetes [19,26,27]. However, some studies
concluded that collaborative care improved depression
outcome alone [23,28]. There is no consensus on these
results. We still do not know whether collaborative care
work as a truly integrated intervention that improve both
depression and diabetes outcomes.
We therefore conducted a systematic review and meta-
analysis to examine whether a primary care based col-
laborative care would improve depression and diabetes
outcomes in patients with both depression and diabetes.
Methods
Publication search
Literature searches were conducted through March 27,
2013 using the electronic databases Medline (1946 to
present), Embase (1980 to present), Cocharne library
(present) and PsycINFO (1806 to present). The detailed
search strategies were shown in Additional file 1. No re-
striction was placed on type of language. We also screened
the references from retrieved articles and reviews to identify
additional articles which met the eligibility criteria.
Study selection
Studies that met the following criteria were included in
this meta-analysis: (1) Participants: both male and female
patients of any age, with a diagnosis of both depression
and diabetes. Diagnosis of depression was according to
one of the following: a, diagnosis made by primary care
physicians; b, current prescription for an antidepressant; c,
diagnosis according to International Classification of
Diseases, Ninth Revision (ICD-9) code, Diagnostic and
Statistical Manual (DSM) and/or Research Diagnostic
Criteria (RDC); d, assessment through clinician-rated and/
or self-rated validated instruments, for example, patient
health questionnaire (PHQ); e, diagnosis made through
structured psychiatric interview. Diagnosis of diabetes wasaccording to one of the following: a, diagnosis made by pri-
mary care physicians; b current prescription for a glucose
lowering medication; c, diagnosis according to ICD-9 code;
d, diagnosis according to laboratory result. (2) Type of
intervention: although there was considerable variability in
the exact nature of the intervention [29], we regarded that
if it fulfilled the following four criteria as the intervention
of collaborative care: a, a multi-professional patient care; b,
a structured management plan; c, scheduled patient follow
up; d, enhanced inter-professional communication [30].
(3) Type of control: we regarded it as control according to
one of the following: a. no additional intervention was
provided; b. usual care was provided in the control group;
c. enhanced usual care was provided in the control group.
(4) Type of outcome measurements: the studies were
included if one of the following outcomes were reported
in the original article: a, depression treatment response; b,
depression remission; c, hemoglobin A1c (HbA1c) control;
d, adherence to medication (including adherence of oral
hypoglycemic agents and/or antidepressants); (5) Type of
studies: only clinical randomized controlled trials (RCTs)
or cluster RCTs were eligible; (6) Setting: primary care
settings.
Studies that did not meet the above criteria were
excluded. In addition, those duplicated publications
were excluded. Two authors (YH TW) independently
evaluated the articles for inclusion. Any discrepancies
were resolved by further discussion and consultation of a
third author (XW). The selection process by means of a
flow chart was presented in Figure 1.Data extraction
A standardized data extraction form was used. The fol-
lowing information was extracted: first author name,
publication year, country of corresponding author, study
design, study period, age, gender, ethnicity, sample size
(intervention/control), length of follow-up, conflicts of
interest (Table 1), inclusion criteria of patients, description
of “collaborative care” and “control”, main outcomes (see
Additional file 2). All the corresponding authors of studies
included in qualitative synthesis were contacted by e-mail
a maximum of 3 times to obtain additional information.
However, no information was received from the original
authors.Quality assessment
The risk of bias for the included studies was assessed
using the Cochrane Collaboration’s tool for assessing
risk of bias [34]. Two authors (XW TW) independently
assessed the methodological quality of RCTs using the
Cochrane risk of bias tools. Any discrepancies were
resolved by a third author (RC).
Figure 1 Flow chart of study selection.
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Primary clinical outcomes of interest, evaluated at the end
of follow up, 6 months and 12 months of follow up (during
which patients were on collaborative care intervention)
respectively, included depression treatment response
(defined as 50% or more decrease in the Hopkins Symp-
toms Checklist-20 (SCL-20) score from base line); depres-
sion remission (defined as SCL-20 score less than 0.5);
diabetes clinical outcomes (HbA1c values) (defined as
HbA1c measures exposure of red blood cells to glucose
during a 90-day period). Secondary outcomes were
adherence (defined as the percentage of prescribed doses
taken, calculated as the number of doses taken divided by
the number of doses prescribed over the observationperiod * 100%) to antidepressant medication and oral
hypoglycemic agent (which was dichotomized at a thresh-
old of 80%) [35].
We used Revman software (version 5.2), which was avail-
able through the Cochrane Collaboration (www.cochrane.
org). Heterogeneity was quantified with a Chi-square het-
erogeneity statistic and by means of I square, with a pre-
defined significance threshold of 0.1 [36]. If a significant
trend for heterogeneity was observed, a random effect
model via generic inverse variance weighting was used to
combine the effect [37]. Otherwise, we used a fixed-effects
model to calculate the pooled effects. Results were
expressed as the relative risks (RRs) with 95% confi-
dence intervals (CIs) for dichotomous variables and
Table 1 Characteristic of the included studies
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variables. Results were considered statistically signifi-
cant when P < 0.05. The possibility of publication bias
was initially planned to be evaluated by funnel plots,
but not adopted eventually either because of the limited
number of trials included or the significant heterogeneity
among trials [38]. No additional analysis was performed.




We identified 1,467 citations (Figure 1). After excluding
103 duplicate records, two authors (YH XW) screened
1,364 titles and abstracts to identify the potentially rele-
vant studies. Totally 217 full-text articles were assessed
for eligibility. Of these, 10 studies were included in
qualitative synthesis [2,19,23,24,26,27,31-33]. A total of 8
articles met the final eligibility criteria for meta-analysis
[19,23,26,27,31-33]. The detailed selection process was
described in Figure 1.
Characteristics of the included studies
Table 1 summarized the basic characteristics of the
included randomized controlled trials. There were 8
studies with a total of 2,238 patients with both depression
and diabetes, which compared collaborative care with
usual care [19,23,26,27,31-33]. All trials were from the
United States. One trial included only African Americans
[27]. Two trials included only old patients (aged or above
50 and 60 respectively) [27,28]. Three trials used enhanced
usual care for the control group [19,31,32] and five trials
used normal usual care [23,26-28,33]. Duration of trials
varied from 13 months to 30 months.
Random sequence generation [23,28,31,32] and allocation
concealment [19,23,28,32] were described adequately
in four studies respectively. Blinding of patients was
not possible. Therefore, all studies had high risk of bias in
blinding. Five studies [19,23,28,36,38,] described adequate
blinding of outcome assessment. Two studies [19,23]
did not provide sufficient information for assessment
of incomplete outcome data. Six studies [19,23,28,31-33]
reported all expected outcomes. The detailed risk of bias
of all included trials was shown in Table 2.
Depression treatment response and depression remission
at the end of follow up
Four trials provided information on treatment response
rate to calculate the overall effect size, with 1,096 patients
[19,23,32,33]. The length treatment ranged from 12 to
24 month. All of these trials reported an increased
treatment response rate in the collaborative group, and
one was significant (RR = 1.96, 95% CI = 1.38-2.78) [19].
Pooling of the mean proportion showed that 44.8% ofpatients in intervention group and 34.3% of patients in
control group had treatment responses. The meta-analysis
showed that collaborative care was associated with a
significant increase in treatment response rate at the
end of follow up (RR = 1.33, 95% CI = 1.05-1.68; P = 0.06
for heterogeneity; I2 = 59%) (Figure 2A). The RR of 1.33
indicated a 33% relative increase in treatment response
rate was added to collaborative care. There was significant
heterogeneity in the studies.
Two trials reported information on depression remission
rate [32,33]. Of these, one showed a significant improve-
ment on remission rate in collaborative care group at the
end of the 24 month’s treatment (adjusted RR = 1.53, 95%
CI =1.11-2.12) [32]. Another reported a non-significant
improvement [33]. There were 552 patients to calculate
the overall effect size. The meta-analysis indicated that
there was a non-significant effect of collaborative care
(RR = 1.15, 95% CI = 0.87-1.52; P = 0.33 for heterogeneity;
I2 = 0%) (Figure 2B).Depression treatment response at 6 and 12 months
follow up
Four trials evaluated treatment response rate at 6 months
follow up, with totally 1,118 patients [19,23,32,33]. All
reported an increased treatment response rate in the
collaborative group, and three were significant. Combining
the four trials also demonstrated a statistically significantly
beneficial effect of collaborative care at 6 months follow
up (RR = 1.64, 95% CI = 1.28-2.10; P = 0.09 for heterogen-
eity; I2 = 54%) (Figure 3A).
Four trials provided information to calculate the overall
effect size of treatment response rate at 12 months follow
up, with 1,344 patients [19,23,32,33]. All of these trials
reported an increased treatment response rate in the collab-
orative group, and two were significant. The meta-analysis
showed that collaborative care was associated with a signifi-
cant increase in treatment response at 12 months follow up
(RR = 1.42, 95% CI = 1.14-1.76; P = 0.10 for heterogeneity;
I2 = 52%) (Figure 3B).Depression remission at 6 and 12 months follow up
Two trials reported depression remission rate at 6 months
follow up, with an evaluation of 595 patients to calculate
the overall effect size [32,33]. Both of the trials reported
an increased treatment response rate in the collaborative
group, neither of them was significant. However, the com-
bined results indicated a significant increase with collab-
orative care (RR = 1.33, 95% CI = 1.01-1.75; P = 0.70 for
heterogeneity; I2 = 0%) (Figure 3C).
Two trials reported information on depression remission
at 12 months follow up, with an evaluation of 569 patients
to calculate the overall effect size [32,33]. The meta-analysis
resulted in a non-significant effect on depression remission
Table 2 The risk of bias of included studies




















Bogner et al. [26] 2012 U U H U L U U
Bogner et al. [27] 2010 U U H U L U U
Ciechanowski et al. [31] 2006 L U H L L L U
Ell et al. [32] 2011 L L H L L L U
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Williams Jr et al. [28] 2004 L L H L L L U
H high risk of bias, L low risk of bias, U unclear risk of bias.
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P = 0.48 for heterogeneity; I2 = 0%) (Figure 3D).
Diabetes clinical outcomes (HbA1c values) at the end
of follow up
Seven trials reported HbA1c values. One trial [26] showed
a significant reduction on HbA1c values in collaborative
care group at the end of follow up. Another trial [24]
showed that the percentage of patients with HbA1c values
less than 7 was 60.9% and 35.7% in collaborative care
group and usual care group respectively (no statistical
analysis provided). The other five trials [19,23,27,28,32]
provided information to calculate the overall effect size atFigure 2 Depression treatment response and remission at the end of
from meta-analysis of diabetic depression patients with collaborative care (
patients with treatment response. (B) Number of patients with depressionthe end of follow up, with totally 1,094 patients. Of these,
only one was significant (MD= -0.48, 95% CI = -0.91–0.05)
[19]. The analysis of the pooled data from the five trials
demonstrated a reduction in HbA1c values at the end of
follow up in favor of collaborative care (MD = -0.13,
95% CI = -0.46-0.19; P = 0.08 for heterogeneity; I2 = 51%)
although this was not statistically significant (Figure 4).
Diabetes clinical outcomes (HbA1c values) at 6 and
12 months follow up
Four trials evaluated HbA1c values at 6 months follow
up, with 1,101 patients to calculate the overall effect size
[19,23,28,32]. There was a non-significant reduction infollow up. Depression treatment response and remission estimated
intervention group) versus usual care (control group). (A) Number of
remission.
Figure 3 Depression treatment response and remission at 6 and 12 months. Depression treatment response and remission estimated from
meta-analysis of diabetic depression patients with collaborative care (intervention group) versus usual care (control group). (A) Number of
patients with treatment response at 6 months. (B) Number of patients with treatment response at 12 months. (C) Number of patients with
depression remission at 6 months. (D) Number of patients with depression remission at 12 months.
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95% CI = -0.24-0.12; P = 0.31 for heterogeneity; I2 = 16%)
(Figure 5A).
Four trials evaluated HbA1c values at 12 months follow
up, with 1,053 patients to calculate the overall effect size
[19,23,28,32]. The analysis of the pooled data from the
four trials demonstrated a reduction in HbA1c values
at 12 months follow up in favor of collaborative care(MD = -0.07, 95% CI = -0.28-0.13; P = 0.20 for hetero-
geneity; I2 = 36%) although this was not statistically
significant (Figure 5B).
Adherence to antidepressant medication and oral
hypoglycemic agent
Four trials reported rates of adherence to antidepressant
medication, all provided information to calculate the
Figure 4 Diabetes clinical outcomes (HbA1c values). HbA1c values were estimated from meta-analysis of diabetic depression patients with
collaborative care (intervention group) versus usual care (control group).
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891 patients. All the four trials reported a significant im-
provement on adherence to antidepressant medication.
The meta-analysis also indicated a statistical significant
positive effect on rates of adherence to antidepressant
medication (RR = 1.79, 95% CI = 1.19-2.69; P < 0.001 for
heterogeneity; I2 = 84%) (Figure 6A).
Two trials provided information to calculate the pooled
effect size on adherence to oral hypoglycemic agent, with a
total of 238 patients [26,27]. Both of them showed a signifi-
cant improvement on adherence to oral hypoglycemic
agent. The pooled data indicated that collaborative care
was associated with a significant improvement of adherence
to oral hypoglycemic agent (RR = 2.18, 95% CI = 1.61-2.96;
P = 0.60 for heterogeneity; I2 = 0%) (Figure 6B).Figure 5 Diabetes clinical outcomes (HbA1c values) at 6 and 12 mont
depression patients with collaborative care (intervention group) versus usu
values at 12 months.Discussion
The present study comprehensively summarized current
evidences from 8 RCTs to examine if collaborative care
can work as a truly integrated intervention to improve
both depression and diabetes outcomes, comparing with
usual care. We found that collaborative care significantly
improved depression outcomes, as well as adherence to
antidepressant medication and oral hypoglycemic agent.
Though there were significant heterogeneity in the
meta-analyses, we found results from large RCTs were
consistent [19,31,32], which strengthened the robustness
of our conclusion.
Our study showed that collaborative care improved
depression treatment response of diabetic patients with
depression. All combined results showed positive effectshs. HbA1c values were estimated from meta-analysis of diabetic
al care (control group). (A) HbA1c values at 6 months. (B) HbA1c
Figure 6 Adherence to antidepressant medication and oral hypoglycemic agent. Adherence to antidepressant medication and oral
hypoglycemic agent were estimated from meta-analysis of diabetic depression patients with collaborative care (intervention group) versus usual
care (control group). (A) Number of patients with adherence to antidepressant medication. (B) Number of patients with adherence to oral
hypoglycemic agent.
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and the end of follow up. Moreover, the improvement in
the outcome at the end of follow up compared favorably
with response rates in collaborative care trials, which
included patients with and without long term condi-
tions. For example, a previous meta-analysis of 79
RCTs of collaborative care for depression showed a RR
of 1.29 (95% CI = 1.18-1.41) [12] versus a RR of 1.33
(95% CI = 1.05-1.68) in our study.
Collaborative care model was also significantly associ-
ated with higher rates of both adherence to antidepres-
sant medication (RR = 1.79, 95% CI = 1.19-2.69) and oral
hypoglycemic agent (RR = 2.18, 95% CI = 1.61-2.96) in
depressed patients with diabetes. These results are encour-
aging. Previous studies showed that depression was signifi-
cantly associated with poor adherence to medication in
diabetic patients [8,15,39]. In view of the challenges that
faced by physicians in primary care practices, collaborative
care are most likely helpful to improving adherence rate
of medication among depressed patients with diabetes.
The effects of collaborative care on depression remission
rates were limited at the end of follow up. According to
our combined results, it seems that collaborative care did
not benefit long term depression remission (RR = 1.15, 95%
CI = 0.87-1.52). This data was mainly based on the crude
RRs or crude odds ratios (ORs) that reported in original
RCTs. Most of the authors of these original RCTs only
reported the crude RRs or ORs without adjusting the
potential confounders (for example, age, base line SCL-20and HbA1c values). In study of Ell et al [32], the au-
thors anticipated these confounders and provided the
adjusted analysis for collaborative care versus usual
care, which showed a signification increase in depression
remission at the end of follow up (adjusted RR = 1.53, 95%
CI =1.11-2.12). However, the data could not be combined
since there was only one study reported the adjusted
results of this outcome. In the future, the trialists are
recommended to report both adjusted and unadjusted
results to prevent the potential selection bias [40,41]. In
addition, our meta-analysis showed that collaborative care
also improved treatment remission rates at 6 months
follow up, but this effect was modest.
Out meta-analyses showed that the improvements of
outcomes of depression were not accompanied by signifi-
cant differences in HbA1c values between patients in col-
laborative care and usual care group. HbA1c values were
not affected at 6 months, 12 months and the end of follow
up. Of the trials included in qualitative synthesis, three of
them [19,26,27] had found that collaborative care was
associated with improved HbA1c values, and two of them
was significant [19,26]. Given that diabetic patients with
depression usually have more macrovascular and micro-
vascular complications and higher numbers of risk factors
than diabetic patients without depression, the collaborative
care that focuses on improving management of both
depression and diabetes are likely to be needed in the
future, to improve clinical outcomes at a population level
in both of chronic illnesses [19].
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Combining the results from different trials generated
significant variations in outcomes. In meta-analyses of
primary outcomes, there existed a significant heterogeneity
in the overall results of depression treatment response.
The values of I2 are 54%, 52% and 59% for treatment
response at 6 months, 12 months and the end of follow
up respectively, which were all represented moderate
levels of heterogeneity [42]. We therefore used random
effects models to combine the data of these outcomes.
Collaborative care is a kind of complex intervention with
a considerable variability involving separate mechanisms,
which is difficult to specify and define [29]. Nevertheless,
compared with previous reviews [22,43], which using
broader inclusion criteria for collaborative care, this re-
view was based on more precise definition of collaborative
care [12,30].
We were unable to collect addition information from
authors who were responded for the original studies.
There might be some missing data. In addition, using the
Cochrane Collaboration’s tool for assessing risk of bias, we
have identified methodological limitations in the studies.
For example, all studies were rated as high risk of bias for
blinding of participants and personnel.
Last but not least, this meta-analysis was based on 8
RCTs with 2,238 patients from different primary care
practices in the United States, which might not be repre-
sentative of all patients with both diabetes and depression
around the world. Further research is needed to help clarify
whether collaborative care can be implemented outside the
United States.
Conclusions
In summary, collaborative care model significantly improves
depression outcomes and adherence to medication in
diabetic patients with depression, comparing with usual
care. Collaborative care is recommended for patients
with both depression and diabetes in the future.
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